Abbott Laboratories (ABT) News and Stock Outlook on Dec. 25, 2025: FDA Clears Volt PFA, FreeStyle Libre Alert Persists, Exact Sciences Deal Looms
Dec. 25, 2025 — Abbott Laboratories (NYSE: ABT) heads into the year-end stretch with a rare mix of near-term product momentum and headline-level risk management. Over the past several weeks—culminating in key December announcements—Abbott has (1) secured U.S. FDA approval for a next-generation atrial fibrillation ablation platform, (2) expanded its push into consumer biowearables, (3) navigated an FDA early alert tied to certain FreeStyle Libre sensors, and (4) doubled down on its diagnostics ambitions with a planned ~$23 billion enterprise-value acquisition of Exact Sciences. With U.S. markets closed for Christmas Day, investors are largely assessing Abbott based on its most
